Skip to main content
BRAIN Biotech AG logo

BRAIN Biotech AG — Investor Relations & Filings

Ticker · BNN ISIN · DE0005203947 LEI · 391200JKPVHLD6JLZ107 F Professional, scientific and technical activities
Open in API
Filings indexed 368 across all filing types
Latest filing 2022-02-01 M&A Activity
Country DE Germany
Listing F BNN

About BRAIN Biotech AG

https://www.brain-biotech.com/

BRAIN Biotech AG is an industrial biotechnology company specializing in the discovery, development, and production of specialty enzymes, high-performance microorganisms, and bioactive compounds. The company provides tailor-made biosolutions and contract research and development (R&D) services to partners in the food, chemical, and life sciences sectors. Core competencies include enzyme technology, microbial strain development, and bioprocess development. By leveraging an advanced technology portfolio, which includes proprietary platforms for enzyme discovery and genome editing, the company enables its partners to create more sustainable and efficient industrial products and processes, contributing to the bioeconomy.

Recent filings

Filing Released Lang Actions
BRAIN Biotech AG: BRAIN Group expands its food enzyme business with the acquisition of a majority of Breatec B.V. and Comix
M&A Activity Classification · 100% confidence The document is explicitly labeled as an 'Ad-hoc' announcement dated February 1, 2022, disclosing 'inside information acc. to Article 17 MAR'. The content details the acquisition of a majority stake in Breatec B.V. and Comix by BRAIN Biotech AG. This type of material event disclosure, which is not a standard periodic report (like 10-K or IR) or a specific shareholder vote result, falls best under the general category for regulatory announcements that don't fit elsewhere, which is 'Regulatory Filings' (RNS). It is a mandatory disclosure of a significant corporate event (M&A activity), but since 'M&A Activity' (TAR) is defined for merger *proposals* or *takeover bids*, and this is a completed acquisition announcement under MAR disclosure rules, RNS serves as the most appropriate general regulatory filing category for this specific ad-hoc disclosure.
2022-02-01 English
BRAIN Biotech AG: Bekanntmachung der Einberufung zur Hauptversammlung am 09.03.2022 in Offenbach am Main mit dem Ziel der europaweiten Verbreitung gema 121 AktG
AGM Information Classification · 100% confidence The document is explicitly titled 'Einladung zur ordentlichen Hauptversammlung' (Invitation to the Annual General Meeting) and details the agenda for a meeting scheduled for March 9, 2022. The agenda items include the presentation of the annual financial statements, discharge of the board and supervisory board, election of auditors, and a resolution regarding the creation of new authorized capital (Genehmigtes Kapital 2022 / I). The presence of an invitation, agenda, and specific resolutions for a shareholder meeting clearly identifies this document as related to the Annual General Meeting (AGM). Therefore, the appropriate classification is AGM-R.
2022-01-28 German
Annual financial report 2020/2021
Annual Report Classification · 100% confidence The document is explicitly titled 'Annual Report 2020/21' for BRAIN Biotech AG. It contains comprehensive sections including a letter from the CEO, consolidated financial statements, management reports, and auditor's report references. It is a full-length annual report, not an announcement or a summary. FY 2021
2022-01-18 English
BRAIN Biotech AG publishes Annual Report for FY 2020/21
Report Publication Announcement Classification · 99% confidence The document explicitly states in the headline and body: "BRAIN Biotech AG publishes Annual Report for FY 2020/21". This indicates the document is an announcement *about* the release of the full Annual Report. However, the document text itself contains substantial financial highlights, segment performance details, management commentary, and a link to the full report. The length (9583 chars) is significant, suggesting it is more than just a brief notification. In many regulatory contexts, the press release summarizing the key findings of the Annual Report (which often accompanies the filing of the 10-K or equivalent) is classified based on the content provided. Since the text details the full fiscal year results (FY 2020/21), it functions as the primary summary of the annual performance. While it announces the 'Annual Report', the content provided is the detailed summary of the annual results, which aligns closely with the scope of an Annual Report (10-K) summary or a comprehensive Earnings Release (ER) for the full year. Given the explicit mention of 'Annual Report' and the comprehensive nature of the financial review for the entire fiscal year, the most appropriate classification is the Annual Report (10-K) or, if this is the press release accompanying it, the Earnings Release (ER) for the full year. Since the definition for 10-K is 'Official yearly report covering company activity and full financial performance,' and this document summarizes that performance, 10-K is the intended target document type being announced. If this were a quarterly report, it would be IR. Since it is the full year, 10-K is the best fit, as the content is the summary of the full year's performance, even if it's technically the press release announcing the filing.
2022-01-17 English
BRAIN Biotech AG: BRAIN-Engineered-Cas (BEC) Considered a Patentable Technology
Legal Proceedings Report Classification · 99% confidence The document is a press release dated January 11, 2022, disseminated via DGAP, which is a service for corporate news and regulatory announcements. The content focuses on a significant development regarding intellectual property: receiving a favorable written opinion from the European Patent Office (EPO) concerning the patentability of their BRAIN-Engineered-Cas (BEC) technology. This is a specific update on IP/patent progress, not a full financial report (10-K, IR), an earnings release (ER), or a management change (MANG). While it relates to intellectual property, the most fitting category among the provided options for a general, non-financial, non-management, non-voting, non-dividend, non-share transaction announcement that is regulatory in nature and concerns legal/IP status is often the general Regulatory Filings (RNS) or potentially Intellectual Property (IP). Given the specific focus on patent filing status and the EPO report, 'IP' (Intellectual Property) is a strong candidate if available. Reviewing the list, 'IP' (Code: IP) is defined as 'Investor Presentation'. Since this is a press release about a patent finding, and not an investor presentation, 'IP' is incorrect. The document is a general corporate news announcement about a legal/patent milestone, which fits best under the broad 'Regulatory Filings' (RNS) category, as it is a formal announcement disseminated through a regulatory news service (DGAP) that doesn't fit the more specific financial or corporate action codes. However, since the content is explicitly about patent applications and IP protection, and 'IP' is listed as 'Investor Presentation', I must re-evaluate. The content is a formal announcement of a legal/IP status update. If 'LTR' (Legal Proceedings Report) is for lawsuits, this is the opposite (a positive legal finding). Given the options, 'RNS' (Regulatory Filings) serves as the best general category for significant, non-financial, non-management corporate news disseminated via official channels like DGAP, especially when a more specific IP/Patent code is not available or misaligned (like the definition for 'IP'). I will classify it as RNS as it is a general regulatory news dissemination.
2022-01-11 English
BRAIN Biotech AG: BRAIN-Engineered-Cas (BEC) Considered a Patentable Technology
Regulatory Filings Classification · 98% confidence The document is classified as an 'Ad-hoc' announcement dated January 11, 2022, disclosing inside information according to Regulation (EU) No 596/2014 (MAR). The content specifically discusses receiving a favorable written opinion from the European Patent Office (EPO) regarding the patentability of their BRAIN-Engineered-Cas (BEC) technology. This is a specific corporate event disclosure, not a comprehensive financial report (like 10-K or IR), a management discussion (MDA), or a standard earnings release (ER). Since it is a specific regulatory disclosure concerning intellectual property/legal status that doesn't fit the other specific categories (like DIRS, DIV, CAP, etc.), the most appropriate general regulatory category is 'Regulatory Filings' (RNS), as it is a mandatory disclosure under EU regulations that doesn't map to a more specific financial or governance report type listed.
2022-01-11 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.